Amager Hospital, Denmark, Implements Comprehensive suPAR Measurement for Acute Patient Care

Amager Hospital in Denmark has partnered with ViroGates to integrate suPARnostic® TurbiLatex into regular clinical procedures, using the system for triaging and assessing the severity of acute clinical patients in the Emergency Room.

The hospital, overseen by the Capital Region, attends to around 50,000 patients annually, with approximately 16,000 requiring admittion or hospitalization.

Professor Ove Andersen, Dm.Sc, MD, comments, “In recent years, suPAR has proven to be a robust risk marker in acute medical patients, regardless of the clinical signs used for patient triage. Including suPAR enhances risk prediction for both low- and high-risk acute medical patients, supporting the decision-making process for admission or discharge. We’re pleased that Amager Hospital now has access to the knowledge provided by suPAR.”

CEO Jakob Knudsen states, “We’re delighted to announce another clinical customer adopting suPARnostic® for the risk assessment of acute clinical patients. Moreover, we’re pleased that Amager Hospital will be the first to implement the newly developed suPARnostic® TurbiLatex product in its clinical biochemistry laboratory on the Roche Diagnostics cobas instrument. We anticipate collaborating with other hospitals to address the challenges posed by the increasing number of patients with co-morbidities, making risk assessment difficult. The availability of suPARnostic® will improve risk assessment, leading to better clinical decisions, enhanced patient care, and optimized hospital resources.”